J. Goldman & Co LP Invests $1.51 Million in Trevi Therapeutics, Inc. $TRVI

J. Goldman & Co LP purchased a new position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 80,998 shares of the company’s stock, valued at approximately $1,511,000. J. Goldman & Co LP owned 0.06% of Trevi Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. KBC Group NV bought a new stake in shares of Trevi Therapeutics during the 1st quarter worth about $29,000. Hilton Head Capital Partners LLC acquired a new position in shares of Trevi Therapeutics during the fourth quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Trevi Therapeutics during the fourth quarter valued at approximately $50,000. Russell Investments Group Ltd. raised its holdings in Trevi Therapeutics by 194.5% during the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock worth $25,000 after purchasing an additional 2,996 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Trevi Therapeutics by 32.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock worth $78,000 after purchasing an additional 1,523 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

Wall Street Analysts Forecast Growth

TRVI has been the topic of several research analyst reports. BMO Capital Markets assumed coverage on Trevi Therapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $36.00 price target on the stock. Stifel Nicolaus set a $30.00 target price on Trevi Therapeutics in a research note on Friday, May 8th. B. Riley Financial lifted their target price on Trevi Therapeutics from $21.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Friday, July 17th. Finally, HC Wainwright upped their price target on shares of Trevi Therapeutics from $21.00 to $24.00 and gave the company a “buy” rating in a report on Monday, July 20th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $27.08.

Trevi Therapeutics Trading Down 0.7%

TRVI stock opened at $17.95 on Wednesday. Trevi Therapeutics, Inc. has a one year low of $6.93 and a one year high of $20.22. The firm has a market capitalization of $2.56 billion, a PE ratio of -52.79 and a beta of 1.03. The firm has a 50-day moving average of $18.01 and a two-hundred day moving average of $14.66.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Thursday, August 6th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). On average, equities research analysts anticipate that Trevi Therapeutics, Inc. will post -0.48 earnings per share for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.